CLL-1: An emerging target for immunotherapy in acute myeloid leukemia
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-06916-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2026. Verfasst von Yu Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Qiaokou Dis…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Immunotherapy, Receptors, Mitogen, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
AML is an aggressive haematological malignancy characterised by uncontrolled proliferation and differentiation arrest of myeloid progenitor/stem cells. Conventional treatment methods principally entail chemotherapy and haematopoietic stem cell transplantation; however, the efficacy of these treatments is constrained by the occurrence of relapses and treatment-related toxicity. In recent years, research into molecular mechanisms has driven the development of targeted therapies against specific gene mutations and advanced multiple immunotherapy strategies. Among these, C-type lectin-like molecule 1 (CLL-1) has emerged as a promising new immunotherapy target due to its specific expression in AML blast cells and leukemia stem cells. CLL-1-targeted therapies have been shown to have the potential to alleviate drug resistance, reduce non-specific toxicity, and address issues of immune escape. This review provides a comprehensive summary of the latest research advances in CLL-1-targeted therapies for AML, with the aim of providing novel insights and directions for clinical treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Qiaokou District, Wuhan, 430030, Hubei, P.R. China.
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Qiaokou District, Wuhan, 430030, Hubei, P.R. China. yixiao@tjh.tjmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., & Xiao, Y. (2026). CLL-1: An emerging target for immunotherapy in acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-06916-2
Vancouver
Wang Y, Xiao Y. CLL-1: An emerging target for immunotherapy in acute myeloid leukemia. Annals of Hematology. 2026. doi:10.1007/s00277-026-06916-2
BibTeX
@article{Wang2026,
author = {Wang, Yu and Xiao, Yi},
title = {CLL-1: An emerging target for immunotherapy in acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-06916-2}
}
EUVIMED